Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis
NCT ID: NCT01588483
Last Updated: 2023-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
163 participants
OBSERVATIONAL
2012-03-01
2023-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this prospective study is to follow-up on the aortic diameter, and to correlate these measures with FDG-PET uptake at diagnosis. Ideally, this would allow us to define a group of patients at high risk to develop an aortic aneurysm, already at the time of diagnosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VCRC Longitudinal Protocol for Aortitis
NCT03022331
Biomechanical and Microstructural Properties of Ascending Aortic Aneurysms
NCT03142074
Development of Novel Imaging Markers Predicting the Progression of Abdominal Aortic Aneurysm Using 3D Computed Tomography
NCT04333641
Venous Distension in Patients With Aneurysmatic Arterial Disease
NCT02867501
Prevalence of Carotid Artery Stenosis and Abdominal Aortic Aneurysms in Brussels: a Population-based Screening Study.
NCT04098523
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Measurements include the diameter of the ascending aorta, aortic arch, descending aorta, suprarenal, juxtarenal and infrarenal aorta, and the volume of the thoracic and the abdominal aorta. These measurements are correlated with FDG-uptake at the level of the aorta on PET-scintigraphy at the time of diagnosis. All patients will be treated according to accepted guidelines and standard care in our center (methylprednisolone started at 32 mg/day, with slowly declining doses until stop after 1 to 1,5 years of treatment).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
giant cell arteritis
patients with biopsy and/or scintigraphy proven GCA
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with a previous diagnosis of giant cell arteritis, in whom a yearly computed tomography of the aorta is available can opt to participate in this study
* informed consent form has to be signed by all patients
Exclusion Criteria
* earlier episodes of giant cell arteritis, without documentation of the aortic diameter at that moment
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof Daniel Blockmans
prof. dr. Daniël Blockmans
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniël Blockmans, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Gasthuisberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Blockmans D, Coudyzer W, Vanderschueren S, Stroobants S, Loeckx D, Heye S, De Ceuninck L, Marchal G, Bobbaers H. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford). 2008 Aug;47(8):1179-84. doi: 10.1093/rheumatology/ken119. Epub 2008 May 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATACT-study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.